News and Events


RH Nanopharmacuticals Announces that U.S. FDA granted Pre-Investigational New Drug Meeting (Pre-IND) for Salsalate to be held on June 28, 2018

    RHNanopharmacuticals, LLC announces that that the U.S. Food and Drug Administration (FDA) has granted a Pre- Investigational Neww drug (Pre-IND) meeting on June 28,2 018. for the treatment of Osteoarthrtiis, and Rheumatoid arthritis and pain. RHnanopharmacuticals is anticipating to discuss with FDA about other nanoformulations of Salsalate as more animal data is available in coming months.

    Joe, Ross MD, CEO and Cofounder of RHNanopharmacuticals, mentioned" FDA granting of Pre - IND meeting for our Salsalate development program discussion for various formulations including nanoformulation is an important milestone achievement to bring us closer to an alternative to NSAIDS , as a safer analgesic treatment option for people with Osteoarthritis and Rheumatoid arthritis and acute pain in USA".